 |
Farahnaz Forozan, Ph.D., MB(ASCP) Science Advisory Board Member Dr. Farahnaz Forozan has applied her technical, regulatory, clinical operation, and diagnostics expertise in oncology, immuno-oncology, neurology, and microbiomes in roles at Cedar-Sinai Medical Center, Genzume, LabCorp/Covance, and Bristol Myers Squibb. She has consulted with venture capital firms, angel investors, private equity, consulting firms, hospitals, biotech and pharma companies, research academic centers, and CROs. In the course of providing strategy, diligence, market analysis, and scientific intelligence, Dr. Forozan has contributed to complex R&D projects, early-stage, pre-clinical, and clinical stage trials; the assessment of new platforms and technologies; drug discovery, drug development, biomarker identification and development; and assay development. She has also built out translational, diagnostic, and prognostic labs; developed regulatory strategy; and delivered on preclinical & clinical pipeline from discovery through launch. Dr. Forozan has collaborated with companies including Illumina, DAKO, Agilent, Ventana, Leica, Qiagen, NanoString, and Abbott in implementing global, multisite, companion and in vitro diagnostics and device studies in the U.S. as well as China, the EU, and Australia, with direct contributions to regulatory authorities including FDA, cFDA, EMA, and TGA. She contributed to the development, approval, and post-marketing support of more than 15 marketed products and over 30 global programs in various stages of clinical development. Dr. Forozan received her Ph.D. in 2000 with a degree in Genetics through a joint program between The George Washington University and the National Institutes of Health. She received her B.S. in Biology/Genetic engineering from California State University, Los Angeles. She is a Clinical Ph.D. and licensed Clinical Genetic Molecular Biologist Scientist in the State of California. |